(RTTNews) - Halozyme Therapeutics (HALO) announced that argenx's VYVDURA, which is co-formulated with Halozyme's ENHANZE drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare for adults with chronic inflammatory demyelinating polyneuropathy. The MHLW approval is based on the ADHERE Study, the clinical trial studying CIDP.
"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Helen Torley, CEO of Halozyme.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
